Atherectomy Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Directional, Rotational, Laser, Orbital), By Application (Peripheral, Cardiovascular, Neurovascular), By End User (Hospitals & Surgical Centres, Ambulatory Care Centres, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Atherectomy Devices Market, valued at USD 1.12 Billion in 2024, is projected to experience a CAGR of 7.10% to reach USD 1.69 Billion by 2030. Atherectomy devices are specialized medical instruments employed in minimally invasive endovascular procedures to mechanically remove atherosclerotic plaque from blood vessel walls, thereby restoring adequate blood flow. This market's growth is primarily driven by the escalating global prevalence of cardiovascular diseases, particularly peripheral artery disease and coronary artery disease. Concurrently, the increasing aging demographic, which exhibits higher susceptibility to vascular conditions, further fuels demand. The rising preference for minimally invasive treatment modalities, offering reduced recovery times and fewer complications, also significantly contributes to market expansion.

According to the American Heart Association, in June 2023, an estimated over 200 million individuals worldwide were affected by peripheral artery disease, a key indicator of the extensive patient pool requiring atherectomy interventions. Moreover, continuous technological advancements enhancing device precision and safety bolster market adoption. However, a notable challenge impeding market expansion is the high cost associated with atherectomy devices, which can impact accessibility and reimbursement in various healthcare systems.

Key Market Drivers

The two most significant factors driving the growth of the Global Atherectomy Devices Market are the rising prevalence of cardiovascular diseases and the increasing geriatric population. The escalating burden of cardiovascular diseases directly translates into a greater patient pool requiring intervention, including atherectomy procedures. Atherosclerosis, a primary cause of conditions such as peripheral artery disease and coronary artery disease, necessitates mechanical plaque removal to restore blood flow and prevent severe complications. According to the Global Burden of Cardiovascular Diseases and Risks 2023 Collaborators, in their "Global, Regional, and National Burden of Cardiovascular Diseases and Risk Factors in 204 Countries and Territories, 1990–2023" published in *JACC* in September 2025, there were 626 million prevalent cases of cardiovascular disease globally in 2023. This highlights the extensive and current need for effective treatment modalities. Concurrently, the increasing geriatric population significantly amplifies this demand. Older individuals are inherently more susceptible to age-related vascular pathologies, including arterial hardening and plaque accumulation, making them a key demographic for atherectomy interventions. As people live longer, the incidence of these conditions naturally rises. According to the United Nations Department of Economic and Social Affairs, Population Division, in its "World Population Prospects 2022: Summary of Results" released in 2022, 1 in 10 people in the world were aged 60 years or over, indicating a substantial and growing segment of the population at higher risk for vascular diseases. This demographic shift, coupled with improved diagnostics and awareness, leads to an increased number of diagnoses and subsequent treatment referrals for atherectomy procedures. Reflecting this robust demand across the market, Boston Scientific, in its Q3 2023 earnings report on October 25, 2023, stated that its Peripheral Interventions revenue, which includes atherectomy, increased 11.8% on a reported basis in the third quarter of 2023 compared to the prior year period.

These interconnected demographic and epidemiological trends underscore a fundamental and growing requirement for advanced vascular intervention tools. The continuous evolution of these core drivers is expected to ensure sustained expansion for the global atherectomy devices market.

Download Free Sample Report

Key Market Challenges

The elevated cost of atherectomy devices presents a substantial impediment to the growth of the global market. This financial barrier directly affects the accessibility and widespread adoption of these advanced interventional tools within diverse healthcare systems. High procurement costs can strain hospital budgets, particularly in regions with limited healthcare spending, thereby restricting the acquisition and availability of atherectomy technology. This limitation directly impacts the volume of procedures that can be performed, slowing market penetration and expansion.

Furthermore, securing adequate reimbursement for these expensive procedures poses a persistent challenge. Insurers and national health services often scrutinize high-cost interventions, potentially leading to unfavorable reimbursement rates or restrictive coverage policies. According to the American Hospital Association, medical supply expenses, which include devices, collectively accounted for $146.9 billion for U. S. hospitals in 2023, representing an increase of $6.6 billion over 2022. Such increasing financial pressures on hospital budgets, partly driven by the costs of medical supplies, can deter healthcare facilities from investing in high-cost atherectomy devices, thus directly hindering overall market development.

Key Market Trends

The increased adoption of combination therapies involving atherectomy with drug-coated balloons represents a significant market trend. This approach aims to enhance procedural outcomes by mechanically debulking plaque followed by local drug delivery to prevent restenosis, offering a comprehensive solution for complex vascular lesions. Clinicians are increasingly recognizing the synergistic benefits of these combined modalities in improving long-term vessel patency and reducing the need for repeat interventions. According to a meta-analysis published in *PubMed Central* in February 2024, atherectomy combined with drug-coated balloon angioplasty was associated with a 16% higher likelihood of primary patency and a 39% lower risk of target lesion revascularization compared to drug-coated balloon angioplasty alone in the treatment of lower extremity artery disease. This growing body of clinical evidence underscores the therapeutic advantages of integrated strategies, broadening the application of atherectomy devices as a foundational component within advanced interventional protocols. Furthermore, according to the Japanese Association of Cardiovascular Intervention and Therapeutics, in 2023, its 'Clinical Expert Consensus Document on Drug-Coated Balloon' endorsed coronary drug-coated balloons, reflecting their growing acceptance in complex coronary interventions.

The procedural shift to outpatient and ambulatory settings is fundamentally reshaping the landscape of atherectomy delivery. This migration is driven by factors such as cost-efficiency, patient convenience, and the increasing capability of minimally invasive techniques to be performed safely outside traditional hospital environments. Ambulatory surgery centers (ASCs) and office-based labs (OBLs) offer reduced overheads and streamlined patient experiences, making them attractive alternatives for select atherectomy procedures. This transition expands patient access to interventions and contributes to the overall growth of the market by increasing the volume of procedures performed. According to the American Hospital Association, in 2023, outpatient atherectomy procedures increased by 25%, indicating a notable preference for these settings. Concurrently, the American College of Cardiology, as reported in the *ASCA News Digest* in February 2024, launched a new data registry specifically designed for cardiac procedures performed in ambulatory surgery centers, highlighting the formal recognition and tracking of this important care delivery shift by a major medical association.

Segmental Insights

The Directional segment is a dominant and rapidly expanding area within the Global Atherectomy Devices Market. This significant growth is primarily attributed to the devices' ability to achieve precise plaque excision with minimal disruption to surrounding healthy arterial tissue, thereby enhancing procedural safety and patient outcomes. Furthermore, continuous technological innovations have improved the efficacy of directional atherectomy for diverse and challenging lesions, particularly in peripheral vascular interventions. Endorsements through regulatory clearances from bodies such as the U. S. Food and Drug Administration further affirm the reliability and increasing adoption of these advanced systems in clinical practice.

Regional Insights

North America leads the Global Atherectomy Devices Market due to a confluence of specific regional advantages. The high prevalence of peripheral artery disease and other cardiovascular conditions in the region drives significant demand for advanced treatment options. This demand is met by a well-established and sophisticated healthcare infrastructure, which facilitates the adoption of innovative atherectomy technologies. Furthermore, favorable reimbursement policies and a robust regulatory framework, including approvals from the U. S. Food and Drug Administration, encourage market growth and device accessibility. The presence of major medical device manufacturers, coupled with substantial research and development investments, consistently introduces new and effective atherectomy solutions to the market.

Recent Developments

• In October 2025, BD (Becton, Dickinson and Company) announced the enrollment of the first patient in its XTRACT Registry. This prospective, multi-center, single-arm, post-market registry study aims to evaluate the real-world clinical performance of the Rotarex Catheter System in treating peripheral artery disease (PAD) lesions. The Rotarex system functions as both an atherectomy and thrombectomy device, employing a rotating atraumatic catheter head designed to efficiently remove plaque and thrombus from peripheral arteries.

• In November 2024, Royal Philips enrolled the first patient in its U.S. THOR IDE clinical trial, evaluating an innovative combined laser atherectomy and intravascular lithotripsy catheter. This breakthrough device integrates two crucial peripheral artery disease (PAD) treatments into a single unit, aiming to simplify the procedural workflow. The trial seeks to assess the safety and efficacy of this dual-function laser-based system in modifying calcium deposits and removing atherosclerotic plaque, potentially advancing treatment strategies for complex vascular conditions.

• In October 2024, Abbott presented key research findings from its ECLIPSE trial concerning the Diamondback 360 orbital atherectomy system. This extensive randomized study evaluated the system's performance in preparing severely calcified coronary arteries for subsequent stent implantation, comparing it against traditional balloon angioplasty. The trial's results indicated that the orbital atherectomy system did not demonstrate superior clinical outcomes over conventional balloon angioplasty for improving results in these challenging coronary lesions.

• In January 2024, AngioDynamics announced the FDA 510(k) clearance of its Auryon XL Radial Access Catheter. This new product is specifically designed for use with the Auryon Atherectomy System to address peripheral arterial disease (PAD). The 225-cm catheter, available in two diameter options, leverages advanced laser technology for effectively treating arterial blockages. Its introduction aims to enhance radial-to-peripheral (R2P) procedures, representing a significant advancement in laser atherectomy technology by offering a non-orbital solution for various lesion types.

Key Market Players

• Braun Melsungen AG
• Abbott Laboratories, Inc.
• Koninklijke Philips N.V.
• Boston Scientific Corporation
• Medtronic plc
• Becton, Dickinson, and Company
• Terumo Corporation
• Cardinal Health Inc.
• AngioDynamics Inc.
• Avinger Inc.

Report Scope:

In this report, the Global Atherectomy Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Atherectomy Devices Market, By Product:

o   Directional

o   Rotational

o   Laser

o   Orbital

• Atherectomy Devices Market, By Application:

o   Peripheral

o   Cardiovascular

o   Neurovascular

• Atherectomy Devices Market, By End User:

o   Hospitals & Surgical Centres

o   Ambulatory Care Centres

o   Others

• Atherectomy Devices Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Atherectomy Devices Market.

Available Customizations:

Global Atherectomy Devices Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Atherectomy Devices Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]